BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT: TXMD) today announced the launch of an underwritten public offering of $125 million of shares of its common stock. TherapeuticsMD also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
